These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Prevention and control of influenza and dengue through vaccine development. Greenberg DP; Robertson CA; Gordon DM Pediatr Ann; 2013 Aug; 42(8):172-7. PubMed ID: 23910031 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of dengue virus strains for human challenge studies. Mammen MP; Lyons A; Innis BL; Sun W; McKinney D; Chung RC; Eckels KH; Putnak R; Kanesa-thasan N; Scherer JM; Statler J; Asher LV; Thomas SJ; Vaughn DW Vaccine; 2014 Mar; 32(13):1488-94. PubMed ID: 24468542 [TBL] [Abstract][Full Text] [Related]
25. Dengue infection: a growing global health threat. Hemungkorn M; Thisyakorn U; Thisyakorn C Biosci Trends; 2007 Oct; 1(2):90-6. PubMed ID: 20103874 [TBL] [Abstract][Full Text] [Related]
31. Dengue: Status of current and under-development vaccines. Redoni M; Yacoub S; Rivino L; Giacobbe DR; Luzzati R; Di Bella S Rev Med Virol; 2020 Jul; 30(4):e2101. PubMed ID: 32101634 [TBL] [Abstract][Full Text] [Related]
32. Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate. Chen HR; Lai YC; Yeh TM J Biomed Sci; 2018 Jul; 25(1):58. PubMed ID: 30037331 [TBL] [Abstract][Full Text] [Related]
33. Dengue/dengue haemorrhagic fever: history and current status. Gubler DJ Novartis Found Symp; 2006; 277():3-16; discussion 16-22, 71-3, 251-3. PubMed ID: 17319151 [TBL] [Abstract][Full Text] [Related]
34. Genome-wide profiling of mRNA and lncRNA expression in dengue fever and dengue hemorrhagic fever. Zhong XL; Liao XM; Shen F; Yu HJ; Yan WS; Zhang YF; Ye JJ; Lv ZP FEBS Open Bio; 2019 Mar; 9(3):468-477. PubMed ID: 30868055 [TBL] [Abstract][Full Text] [Related]
35. Dengue viruses and promising envelope protein domain III-based vaccines. Fahimi H; Mohammadipour M; Haddad Kashani H; Parvini F; Sadeghizadeh M Appl Microbiol Biotechnol; 2018 Apr; 102(7):2977-2996. PubMed ID: 29470620 [TBL] [Abstract][Full Text] [Related]
37. Dengue: a global threat. Thisyakorn U; Thisyakorn C J Med Assoc Thai; 2015 Jan; 98 Suppl 1():S118-22. PubMed ID: 25764623 [TBL] [Abstract][Full Text] [Related]
38. Quantitation of T lymphocyte subsets helps to distinguish dengue hemorrhagic fever from classic dengue fever during the acute febrile stage. Fadilah SA; Sahrir S; Raymond AA; Cheong SK; Aziz JA; Sivagengei K Southeast Asian J Trop Med Public Health; 1999 Dec; 30(4):710-7. PubMed ID: 10928365 [TBL] [Abstract][Full Text] [Related]
39. Dengue vaccine development: Global and Indian scenarios. Swaminathan S; Khanna N Int J Infect Dis; 2019 Jul; 84S():S80-S86. PubMed ID: 30684747 [TBL] [Abstract][Full Text] [Related]
40. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection. Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]